Investors accused the tobacco manufacturer of misleading them about the results of iQOS clinical studies presented to the Food and Drug Administration. The agency’s “July 2020 approval of iQOS as a ‘modified risk tobacco product’ severely undermines any allegations of falsity,” the U.S. District Court for the Southern District of New York said, dismissing the case with prejudice.
Judge Ronnie Abrams threw out most of ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.